Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs

Oncogene

Volumn 32, Issue 6, 2013, Pages 724-735

  Stresing, V ^a,b   Baltziskueta, E ^a   Rubio, N ^c   Blanco, J ^c   Arriba, Mc ^a   Valls, J ^d,e   Janier, M ^f   Clezardin P ^b   Sanz Pamplona, R ^a   Nieva, C ^a   Marro, M ^g   Dmitri, P ^g   Sierra, A ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b INSERM   (France)

^c CSIC   (Spain)

^d UNIVERSITY OF LLEIDA   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f EDOUARD HERRIOT HOSPITAL   (France)

^g ICFO INSTITUT DE CIENCIES FOTONIQUES   (Spain)

Author keywords

angiogenesis; lung metastasis; metabolic stress; oxidative stress; peroxiredoxins

Indexed keywords

GLUCOSE; GREEN FLUORESCENT PROTEIN; HYDROGEN PEROXIDE; PEROXIREDOXIN 2; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELLULAR DISTRIBUTION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG METASTASIS; LYMPH NODE METASTASIS; METABOLIC STRESS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; TUMOR VOLUME;

BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; HYDROGEN PEROXIDE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; OXIDATIVE STRESS; PEROXIREDOXINS; STRESS, PHYSIOLOGICAL; TRANSFECTION;

EID: 84873735490     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.93     Document Type: Article

References (54)

1. Dong F, Budhu AS, Wang XW. Translating the metastasis paradigm from scientific theory to clinical oncology. Clin Cancer Res 2009; 15: 2588-2593.
2. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002; 70: 498-505.
3. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008; 13: 58-68.
4. Nguyen DX, Massagué J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8: 341-352.
5. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65: 9155-9158.
6. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 28: 518-524.
7. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D et al. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007; 17: 6740-6745.
8. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci USA 2007; 104: 19506-19511.
9. Padua D, Zhang XH, Wang Q, Nadal C, Gerald WL, Gomis RR et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133: 66-77.
10. Cairns RA, Harris IS, Mak TW. Regulation of cancer metabolism. Nat Rev Cancer 2011; 11: 85-95.
11. España L, Mart́n B, Aragüés R, Chiva C, Oliva B, Andreu D, et al. Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis, Am J Pathol, 2005, 167, 1125-1137
12. Kim H, Lee TH, Park ES, Suh JM, Park SJ, Chung HK et al. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 2000; 275: 18266-18270.
13. Wen ST, Van Etten RA. The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev 1997; 11: 2456-2467.
14. Rabilloud T, Heller M, Gasnier F, Luche S, Rey C, Aebersold R et al. Proteomics analysis of cellular response to oxidative stress. Evidence for in vivo overoxidation of peroxiredoxins at their active site. J Biol Chem 2002; 277: 19396-19401.
15. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003; 9: 3418-3424.
16. Fujii J, Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 2002; 7: 123-130.
17. Mart?́n B, Sanz R, Aragües R, Oliva B, Sierra A. Functional clustering of metastasis proteins describes plastic adaptation resources of breast-cancer cells to new microenvironments. J Proteome Res 2008; 7: 3242-3253.
18. Chevallet M, Wagner E, Luche S, van Dorsselaer A, Leize-Wagner E, Rabilloud T. Regeneration of peroxiredoxins during recovery after oxidative stress. J Biol Chem 2003; 278: 37146-37153.
19. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 673-678.
20. Iles KE, Forman HJ. Macrophage signaling and respiratory burst. Immunol Res 2002; 26: 95-105.
21. Ganong WF. Gas transport between the lungs & the tissues. In: Weitz M, Brown RY (eds). Ganong's Review of Medical Physiology, Chapter 37, 22 edn. LANGE basic science, McGrow-Hill Companies, USA, 2005. pp 631-697.
22. Archer S, Gomberg-Maitland M, Maitland M, Rich S, Garcia J, Weir K. Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1- Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol 2008; 294: H570-H578.
23. Oláhová M, Taylor SR, Khazaipoul S, Wang J, Morgan BA, Matsumoto K et al. A redox-sensitive peroxiredoxin that is important for longevity has tissue-and stress-specific roles in stress resistance. Proc Natl Acad Sci USA 2008; 105: 19839-19844.
24. Low FM, Hampton MB, Peskin AV. Peroxiredoxin 2 functions as a noncatalytic scavenger of low-level hydrogen peroxide in the erythrocyte. Blood 2007; 109: 2611-2617.
25. Seo JH, Lim JC, Lee DY. Novel protective mechanism against irreversible hyperoxidation of peroxiredoxin: Nalpha-terminal acetylation of human peroxiredoxin II. J Biol Chem 2009; 284: 13455-13465.
26. Tao M, Wang L, Wendt-Pienkowski E, George NP, Galm U, Zhang G et al. The tallysomycin biosynthetic gene cluster from Streptoalloteichus hindustanus E465-94 ATCC 31158 unveiling new insights into the biosynthesis of the bleomycin family of antitumor antibiotics. Mol Biosyst 2007; 3: 60-74.
27. Haraldsen JD, Liu G, Botting CH, Walton JG, Storm J, Phalen TJ et al. Identification of conoidin as a a covalent inhibitor ofperoxiredoxin II. Organic Biomolecular Chem 2009; 7: 3040-3048.
28. Budihardjo I, Walker DL, Svingen PA, Buckwalter CA, Desnoyers S, Eckdahl S et al. 6-Aminonicotinamide sensitizes human tumor cell lines to cisplatin. Clin Cancer Res 1998; 4: 117-130.
29. Buzzai M, Bauer DE, Jones RG, DeBerardinis R, Hatzivassiliou G, Elstro RL et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid-b.oxidation. Oncogene 2005; 24: 4165-4173.
30. Jang Y, Sharkis S. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007; 110: 3056-3063.
31. Wang W, Gou L, Xie G, Tong A, He F, Lu Z et al. Proteomic analysis of interstitial fluid in bone marrow identified that peroxiredoxin 2 regulates H2O2 level of bone marrow during aging. J Proteome Res 2010; 9: 3812-3819.
32. Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004; 111: 514-521.
33. Semenza GL. Tumor metabolism: cancer cells give and take lactate. Commentary. J Clin Invest 2008; 118: 3835-3837.
34. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11: 37-51.
35. Ralser M, Wamelink MM, Latkolik S, Jansen EE, Lehrach H, Jakobs C. Metabolic reconfiguration precedes transcriptional regulation in the antioxidant response. Nat Biotechnol 2009; 27: 604-605.
36. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma? Cancer Res 2009; 69: 5292-5293.
37. Neumann CA, Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 2007; 7: 375-380.
38. Bubici C, Papa S, Dean K, Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006; 25: 6731-6748.
39. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxid Redox Signal 2002; 4: 405-414.
40. Graves JA, Metukuri M, Scott D, Rothermund K, Prochownik EV. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J Biol Chem 2009; 284: 6520-6529.
41. Lee KW, Lee DJ, Lee JY, Kang DH, Kwon J, Kang SW. Peroxiredoxin II restrains DNA damage-induced death in cancer cells by positively regulating JNK-dependent DNA repair. J Biol Chem 2011; 286: 8394-8404.
42. Han YH, Kwon JH, Yu DY, Moon EY. Inhibitory effect of peroxiredoxin II (Prx II) on Ras-ERK-NFkappaB pathway in mouse embryonic fibroblast (MEF) senescence. Free Radic Res 2006; 40: 1182-1189.
43. Méndez O, Fernández Y, Peinado MA, Moreno V, Sierra A. Anti-apoptotic proteins induce non-random genetic alterations that result in selecting breast cancer metastatic cells. Clin Exp Metastasis 2005; 22: 297-307.
44. Peyruchaud O, Serre CM, NicAmhlaoibh R, Fournier P, Clezardin P. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003; 278: 45826-45832.
45. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-1725.
46. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
47. Vanden Hoek TL, Li C, Shao Z, Schumacker PT, Becker LB. Significant levels of oxidants are generated by isolated cardiomyocytes during ischemia prior to reperfusion. J Mol Cell Cardiol 1997; 29: 2571-2583.
48. Román I, Vilalta M, Rodriguez J, Matthies AM, Srouji S, Livne E et al. Analysis of progenitor cell-scaffold combinations by in vivo non-invasive photonic imaging. Biomaterials 2007; 28: 2718-2728.
49. Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11: 204-215.
50. Peyruchaud O, Winding B, Pécheur I, Serre CM, Delmas P, Clézardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J Bone Miner Res 2001; 16: 2027-2034.
51. Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 2002; 16: 1266-1268.
52. El Hilali N, Rubio N, Blanco J. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase. Clin Cancer Res 2005; 11: 1253-1258.
53. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-PLUS. Springer, Germany, 2000.
54. R Development Core Team R. A Language and Environment for Statistical Computing. Foundation for Statistical Computing: Vienna, Austria, 2009.